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Abstract
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The methylglyoxal-derived hydroimidazolones (MG-Hs, Figure 1A) comprise the most prevalent
class of non-enzymatic, post-translational modifications of protein arginine residues found in
nature. These adducts form spontaneously in the human body, and are also present at high levels
in the human diet. Despite numerous lines of evidence suggesting that MG-H–arginine adducts
play critical roles in both healthy and disease physiology in humans, detailed studies of these
molecules have been hindered by a lack of general synthetic strategies for their preparation in
chemically homogeneous form, and on scales sufficient to enable detailed biochemical and
cellular investigations. To address this limitation, we have developed efficient, multi-gram-scale
syntheses of all MG-H–amino acid monomers in 2–3 steps starting from inexpensive, readily
available starting materials. Thus, MG-H derivatives were readily incorporated into oligopeptides
site-specifically using standard solid-phase peptide synthesis (SPPS).
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Access to synthetic MG-H-peptide adducts has enabled detailed biochemical investigations, which
have revealed a series of novel and unexpected findings. First, one of the three MG-H isomers –
MG-H3 – was found to possess potent, pH-dependent antioxidant properties in biochemical and
cellular assays intended to replicate redox processes that occur in vivo. Computational and
mechanistic studies suggest that MG-H3-containing constructs are capable of participating in
mechanistically distinct H-atom-transfer and single-electron-transfer oxidation processes. Notably,
the product of MG-H3 oxidation was unexpectedly observed to disassemble into the fully
unmodified arginine residue and pyruvate in aqueous solution. We believe these observations to
reflect meaningfully on the role(s) of MG-H–protein adducts in human physiology, and expect the
synthetic reagents reported herein to enable investigations into non-enzymatic protein regulation at
an unprecedented level of detail.

INTRODUCTION
Advanced glycation end-products (AGEs) comprise a structurally diverse class of posttranslational protein modifications that form through non-enzymatic chemical processes in
all living organisms, primarily on lysine and arginine side-chains.1,2 Out of more than eight
arginine-derived AGEs reported to date, the methylglyoxal-derived hydroimidazolones
(MG-Hs, Figure 1A) are believed to be the most prevalent in humans.3 Estimates suggest
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that at least one MG-H adduct is present on 3–13% of the proteins found in the human
body,4,5 and that MG-H modifications comprise 1.3% by weight of total protein in heattreated foods (e.g., baked goods, cereals, and dairy products).6
MG-H-protein adducts form both intra-and extracellularly as a mixture of three regioisomers
(Figure 1A), via rapid reactions between arginine and methylglyoxal (MGO), a dicarbonyl
metabolite produced by all living cells.7 Notably, elevated levels of MGO and MG-Hadducts have been shown to induce a range of cellular and subcellular effects including
perturbations in cell signaling, inhibition of protein synthesis and cell growth,8 induction of
oxidative stress and pro-inflammatory cytokine release,9–14 decreases in the adhesive
properties of vascular basement membrane,15 alterations in chaperone function,16 and
numerous other processes.17,18 MGO concentrations have also been observed to increase in
various disease states, including diabetes,19–22 cancer,23 cardiovascular disease,24 and renal
failure.25 Taken together, these observations suggest that MG-H modifications may play a
role in the pathophysiology of these illnesses.
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Despite their putative biological properties and their ubiquity in humans, synthetic studies of
the MG-Hs, and AGEs in general, are in their infancy. Available synthetic procedures for
MG-H adducts are limited to providing products on analytical scales,6 in very low purities,26
or as a subset of the natural isomers.27 The vast majority of published data regarding the
biological functions of MG-Hs has been obtained using highly heterogeneous mixtures
prepared via prolonged incubation of model proteins (such as albumins) with MGO.28
Although these mixtures have provided useful information regarding certain properties and
functions of MGO-protein adducts, their heterogeneous nature complicates efforts to
identify and characterize the specific structure(s) responsible for bioactivity.29 Moreover,
these samples are prone to contamination with varying levels of bioactive impurities (e.g.,
bacterial lipopolysaccharide).30
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Here we report preparative-scale synthetic routes that for the first time afford access to the
entire class of methylglyoxal-derived hydroimidazolones (MG-Hs), both as amino acids and
peptide conjugates. These routes are concise (2–3 steps starting from readily accessible
materials) and high yielding (44–52% overall yield), and MG-H monomers can readily be
incorporated site-specifically into synthetic oligopeptides using automated Fmoc solid phase
peptide synthesis (SPPS). Critically, access to chemically characterized MG-H-containing
peptide constructs has enabled us to perform biochemical evaluations, which have revealed a
series of notable findings. First, we have discovered that MG-H3-containing oligopeptides
are redox-active, both in vitro and in a cellular system. Notably, this redox activity is pHdependent and has a molar potency comparable to that of ascorbic acid. Computational and
mechanistic studies suggest that the MG-H3 core heterocycle possesses a versatile reactivity
profile and is capable of participating in distinct one- and two-electron oxidation processes.
Also, we unexpectedly found that the product of MG-H3 oxidation disassembles
spontaneously in aqueous solution to provide the fully unmodified arginine side-chain and
pyruvate. Taken together, these data suggests that MG-H3 adducts may serve as pHsensitive reducing agents under physiological conditions, leading to spontaneous deglycation of the hydroimidazolone core to regenerate the native arginine side-chain. These
results underscore the significant potential of chemically homogeneous MG-H adducts to
facilitate chemical and biological investigations into these poorly understood species at an
unprecedented level of detail.
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RESULTS
Synthetic Studies
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The arginine-derived hydroimidazoles MG-H1 through MG-H3 (Figure 1A) present
substantial synthetic challenges. These compounds have been reported to decompose
rapidly, and undergo spontaneous ring-opening, H/D exchange, isomerization and
rearrangement reactions.31 Also, because MG-Hs likely exert their biological actions as
peptide- or protein-conjugates in vivo, we required a synthesis that provided AGE-amino
acid monomers suitably protected for Fmoc SPPS (Scheme 1). We therefore designed the
retrosynthetic analysis shown in Figure 1B. We envisioned accessing protected isomeric
MG-H monomers 1–3 via the regioselective cyclization of intermediates 4–6. Regiocontrol
in these ring-forming processes was anticipated to derive from the strategic placement of
functional groups R1 through R3. We also expected that the appropriate protecting groups
could be used to stabilize the acid-and base-labile hydroimidazolone ring during SPPS. Due
to published evidence indicating that the ring methine proton in all three MG-H isomers
rapidly undergoes epimerization or exchange in water,6,32 we decided to target these
compounds first as diastereomeric mixtures. Ultimately, 4–6 could be derived from the
commercial reagent Nα-Fmoc-Nδ-Boc-L-ornithine (7) via simple alkylation and/or
guanidylation processes.33
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Initial efforts focused on a suitably protected MG-H1-arginine adduct. Based on our
preliminary studies, and prior observations suggesting that the MG-H1 isomer is kinetically
disfavored,42 we hypothesized that a blocking group on the ornithine side-chain (e.g., R1 in
4) would be necessary to direct cyclization through the desired pathway. Furthermore, we
discovered that guanidylation required the side-chain N-atom to be electron rich,34 thus
ruling out the majority of common N-protecting groups. After initial experiments, which
revealed that sterically unhindered substituents (e.g., trimethoxybenzyl) led to spontaneous
internal removal of the Fmoc group, we settled on the bis-(4-methoxyphenyl)-methyl (Dod)
group to block the ornithine side-chain (Scheme 1).35,36 Application of this derivative to
Fmoc-ornithine-OBn•HCl (8), followed by HgCl2-promoted coupling with Cbz-thiourea 9,
smoothly provided the corresponding guanidine (10) in good yield (50% over two steps).34
Notably, this two-step sequence could be executed on preparative scales (11.0 g) without
difficulty. Subjection of 10 to catalytic hydrogenolysis cleaved the Cbz and benzyl ester
groups in a single operation, and the resulting intermediate (11), underwent spontaneous
intramolecular cyclization to provide MG-H1 building block 12 as the exclusive product in
88% yield. Overall, this sequence provides 12 in 43% overall yield in only three synthetic
steps, and can be conducted starting with >12 g of ornithine-derivative 8. Two-step removal
of the remaining protecting groups afforded the free MG-H1–arginine adduct as a TFA salt
(12free•TFA), whose spectral properties (1H-NMR, 13C-NMR, and HRMS) agreed well with
literature values reported for a sample isolated from bakery products.6 Assignment of the
hydroimidazolone ring in 12 and 12free as the indicated tautomer was based on calculations
(Table S2) and comparisons with previously reported data in homologous systems.37,38
Having identified a successful route to the MG-H1 monomer (12), we next turned our
attention to MG-H2 (18, Scheme 2). Toward this end, we developed a simple sequence
consisting of reductive amination (8 → 14), guanidylation (14 → 16) and cyclization (16 →
17), which afforded an intermediate iminohydantoin (17) in 55% overall yield.
Chemoselective cleavage of the benzyl ester in 17 provided side-chain- and backboneprotected MG-H2 monomer 18 in only three synthetic steps and in 48% overall yield. Global
protecting group removal proceeded smoothly to yield MG-H2-arginine adduct 18free•TFA,
which matched previously reported spectroscopic data.32,39 Connectivity of 18free•TFA was
also independently confirmed by heteronuclear HMBC coupling between the ring methine
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proton and the side-chain carbon (Figure S5). Tautomeric forms of 18 and 18free were
assigned based upon calculations (Table S3) and comparison to previously reported
simplified systems.37,38
Finally, MG-H3 precursor 22 was obtained simply by rearranging chemical transformations
that had proved successful in the routes above. This sequence (Scheme 3) began with
mercury-mediated guanidylation of 8 with 2,2,4,6,7-pentamethyldihydrobenzofuran-5sulfonyl (Pbf)-derived thiourea 19,46 which afforded an intermediate N,N′-bis-alkylguanidine (20). Although, in theory, pathways for forming either MG-H1 or MG-H3 ring
systems were both accessible via 20, in situ cyclization provided MG-H3 precursor 21 as a
single regioisomer. With 21 in hand, benzyl ester removal provided compound 22 in 64%
yield. Overall, this sequence allowed us to access monomer 22 in only two steps and 52%
overall yield starting from 8. Protecting group removal provided 22free•TFA whose spectral
properties matched previously reported values.32,39 Notably, as for the MG-H1 series
(Scheme 1), synthetic sequences for accessing both MG-H2 and MG-H3 precursors could be
carried out effectively on large scales (6.7–10.7 g). Connectivity assignments in 22free•TFA
were inferred from heteronuclear HMBC couplings between the side-chain protons and the
ring carbonyl carbon (Figure S6). However, the tautomeric preference of 22free could not be
unequivocally established (see Supporting Information).37
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With protected monomeric hydroimidazolone derivatives 12, 18, and 22 in hand, we set out
to construct several AGE-containing oligopeptide sequences. Toward this end, we
synthesized oligopeptides derived from human serum albumin (HSA), site-specifically
substituting the arginine residues with the corresponding hydroimidazolone derivatives
(Table 1). These included HSA fragments (residues 111–120 and 407–415), chosen because
of their established propensities toward glycation in vitro,40,41 and were prepared in good to
excellent yields, with purities universally greater than 95%.37 Spectroscopic data for
peptides 23–25 was found to match perfectly with data previously reported for these
compounds.32,39 Overall, this strategy represents the first feasible route for making AGEpeptide conjugates on large scale, and also enables straightforward access to multiply AGEderivatized constructs (Table 1, entries 8–11).32,39
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Although the ring stereocenters in MG-H1 and MG-H3 have been reported previously to
undergo epimerization,6 the rate of epimerization has not yet been quantified. Thus, we
investigated rates of H/D exchange using constructs 23–25. Dissolution of these peptides as
a formate salt in neat D2O revealed a gradual disappearance of the hydroimidazolone ring αproton for all three MG-H isomers as monitored by 1H NMR spectroscopy. The half-lives of
H/D exchange in these peptides were calculated to equal 40.5, 28.5, and 15.4 hours (Figures
S1–3), respectively.37 Other workers have observed an increase in the rate of epimerization
at pH 5.0 versus 7.4, suggesting that this process may occur rapidly under physiological
conditions.42 Taken together with the mechanism for formation of MG-Hs from an achiral
molecule (MGO), this data suggests that MG-Hs likely exist as thermodynamic mixtures of
diastereomers in the body.
Biochemical Investigations
With various MG-H–peptide constructs in hand, we were intrigued by strong positive
correlations between oxidative stress and AGEs formation, reported in both in vitro and in
vivo assays.43–47 In particular, MGO-protein adducts have been suggested to induce the
formation of reactive oxygen species (ROS) in tissue culture,9–14 and treatment of bovineserum albumin (BSA) with MGO has been shown to cause free radical generation by EPR
spectroscopy.48 Interestingly, glycated proteins believed to contain MG-H adducts have also
been shown to possess anti-oxidant properties in vitro.49,50 Taken together, these

J Am Chem Soc. Author manuscript; available in PMC 2013 May 30.

Wang et al.

Page 5

observations led us to hypothesize that hydroimidazolone adducts might be capable of
participating in redox processes.
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To test this hypothesis, we evaluated the redox activity of MG-H-peptide conjugates 26–29
in vitro, in the MTT and DPPH assay systems (Figure 2). MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide) is a tetrazolium salt that can be reduced to a purple
formazan by mitochondrial enzymes,51 superoxide,52 or direct electron transfer
mechanisms.53 This indicator has been used to measure cell viability,54 superoxide
production,52 and the antioxidant activity of natural products.55 DPPH (1,1-diphenyl-2picryl-hydrazyl), on the other hand, is a stable radical that can be quenched by either
hydrogen atom or proton-coupled electron transfer, and is commonly used to estimate the
ability of substrates to serve as H-atom donors in aqueous media.56 Peptide conjugates
containing the MG-H3 modification (29 and 33) exhibited anti-oxidant activities in both
MTT (Figure 2A) and DPPH (Figure 2B) assays at comparable molar potencies to ascorbic
acid (Vitamin C), an essential nutrient that serves as both an antioxidant57 and enzyme
cofactor.58 Surprisingly, despite their high structural similarities to MG-H3, neither MG-H1
nor MG-H2 exhibited any redox activities under these conditions.
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We also evaluated the effect of pH on the rate of DPPH quenching in the presence of various
MG-H constructs (Figure 2C). Once again, MG-H3 adducts demonstrated significant
activity in this assay, both as peptide conjugate 29, and as the free amino acid monomer
(22free), while MG-H1 and MG-H2 constructs were inactive. Furthermore, the activity of
MG-H3 conjugates was observed to increase at pH values approaching 7, which is
consistent with the results of pKa titrations and computational studies (see Table 2, below).
Interestingly, pH changes were found to exert a far greater effect on DPPH reduction rate for
MG-H3–peptide conjugate 29 than the corresponding free amino acid (22free). Taken
together with observations in MTT assays (Figure 2A), this context-dependent pH
sensitivity indicates the potential for neighboring amino acid residues to influence the
chemical properties of AGEs, and may be an important factor in dictating the processes in
which theses AGEs participate in vivo.
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To determine the cellular relevance of this redox behavior, we explored the effects of MGH–peptide conjugates using a well-established assay protocol.59 Thus, RAW 264.7
macrophages were treated with dihydrorhodamine 123, a cell-permeable fluorogenic probe
converted to a highly fluorescent product on exposure to cellular oxidants in the presence of
varying concentrations of oxidant (H2O2) and MG-H–peptide conjugates.60 As shown in
Figure 2D, MG-H3 conjugate 29 was found to possess a significant level of cellular
antioxidant activity, which was both concentration-dependent (right panel), and robust over
a range of physiologically relevant H2O2 concentrations (left panel, see Supporting
Information for more detail). Interestingly, these effects were slightly smaller in magnitude
than those of ascorbic acid, perhaps due to the relatively poor membrane permeability of this
specific peptide sequence (Supplemental Figure S17). Because MGO and corresponding
MG-H adducts are present physiologically both inside and outside of the cytosol, these data
may underestimate the effects of MG-H3 adducts in vivo. Interestingly, MG-H2 conjugate
28 was found to possess detectable antioxidant effects, which were only revealed under
conditions of variable H2O2 concentration. This observation suggests that MG-H2 adducts
may also possess cellular redox activities that emerge under conditions of high oxidative
stress. As before, MG-H1 conjugate 27 was found to be inactive in this assay. Taken
together, these studies demonstrate the capacity of MG-H3–peptide conjugates to serve as
antioxidants in a cellular milieu in the context of physiologically relevant reactive oxygen
species.

J Am Chem Soc. Author manuscript; available in PMC 2013 May 30.

Wang et al.

Page 6

NIH-PA Author Manuscript

To characterize the products of redox reactions involving MG-H species, we next performed
LC/MS analyses of MTT assay mixtures using peptides 26–29. These experiments indicated
the formation of a new species (Figure 3A). Mass spectrometric analyses revealed this
newly formed material to be two mass units less than parent peptide 29 (Figure 3B),
suggesting oxidation to the corresponding imidazolone (MG-I3, 34).61 Tandem mass
spectrometry (MS/MS) fragmentation analysis (Figure 3C) further confirmed this decrease
in mass to originate at the MG-H3 residue. Detailed NMR experiments, performed on the
oxidized intermediate 34, further support our proposed structural assignment (Supplemental
Figure S8). Interestingly, the analogous MG-H1-derived imidazolone was postulated in prior
work to form under aerobic conditions in model reactions between MGO and BSA or model
peptides;61,62 however, subsequent studies revealed this structural assignment to be
incorrect, and the adduct initially believed to be the imidazolone was actually the
argpyrimidine modification.62
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Based on the electron-deficient nature of the imidazolone oxidation product, we speculated
that perhaps this material could react with arginine and/or lysine residues to form inter- or
intramolecular crosslinks. Formation of such crosslinks is common in protein glycation
processes, and has been cited as a critical contributing factor in the impact of AGE
formation on protein structure and function.63 Unexpectedly, dissolution of oxidized peptide
34 in physiological buffer led to spontaneous hydrolysis to provide the parent arginine
adduct 26 and pyruvate (35, Figure 3D, Supplemental Figures S9-S11). This hydrolysis
process was found to proceed with first-order kinetics (kobs = 1.84 × 10−5 s−1; t1/2 = 10.5 h)
at a rate compatible with the lifetime of many intracellular proteins (Supplemental Figure
S11). Hydrolysis of imidazolone adducts to provide unmodified arginine residues is
therefore kinetically competent to occur under physiological conditions.64 Notably, these
results provide a novel mechanistic framework through which MG-H3-modified proteins
can directly participate in cellular redox processes and recycle back to unmodified species.
Furthermore, the observation of the pyruvate byproduct in these studies supports the
intermediacy of MG-I3 (34), and also provides evidence that MG-H adducts can nonenzymatically cleave to give rise to a metabolically useful intermediate.
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We next conducted mechanistic studies aimed at obtaining insight into the origin of MGH3’s antioxidant activity. We first prepared derivatives of 29 in which the methine C–H
bond in the MG-H3 core heterocycle was replaced with deuterium. Indeed, the effect of
isotopic substitution on reduction rate differed substantially between the MTT and DPPH
assays; a kinetic isotope effect (KIE) of 1.38 was observed using the former assay system,
and 2.27 using the latter (Supplemental Figures S15–16). The relatively large KIE observed
in DPPH assays supports a mechanism involving C–H/D bond homolysis as the rate-limiting
step,65 while the relatively small KIE for the MTT assay is consistent with speculations that
electron transfer pathways are rate-limiting under these conditions.53 Taken together, these
data suggest that MG-H3 is capable of functioning as an antioxidant by way of two distinct
mechanistic pathways.
To shed light on the observed reactivity differences between MG-H isomers, we performed
a series of pKa titrations and Density Functional Theory (DFT) calculations (B3LYP/6–
311++G(2df, 2p), Table 2). These experiments revealed a number of intriguing features,
which may provide explanations for many of MG-H3’s unique properties. For example,
indications that the MG-H3 core heterocycle (38) possesses C–H bond-dissociation energy
(BDE) and ionization energy (IE) values that are both significantly lower than isomeric
compounds 36 and 37 may explain the multi-modal activity of MG-H3 derivatives in both
MTT and DPPH assays. Furthermore, the observation that 38 possesses a pKa value near
neutrality, taken together with calculations suggesting that protonation of the core
heterocycle (39) increases both BDE and IE, may explain the deleterious effect of
J Am Chem Soc. Author manuscript; available in PMC 2013 May 30.
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decreasing pH on antioxidant activity (Figure 2C). Interestingly, the observed pKa trends for
various MG-H isomers are in agreement with experimental observations of structurally
homologous isomers of creatinine.38,66 Because the observed reactivity differences between
MG-H isomers do not correlate with differences between free energy of oxidation (ΔGox)
values (Table 2), we speculate that they reflect kinetic rather than thermodynamic factors.

DISCUSSION
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Here we disclose robust synthetic routes that enable straightforward incorporation of all
known variations of hydroimidazolone-modified arginine residues into peptides via
automated Fmoc SPPS. These constructs have allowed us to undertake among the first
detailed biochemical investigations into chemically homogeneous MG-Hs. Previously, such
studies have been hampered due to limited availability of preparative-scale synthetic
strategies for peptide-MG-H constructs. Our investigations have revealed a series of
unexpected findings. First, using well-characterized assays to measure redox behavior, we
have determined that adducts containing MG-H3 can serve as potent antioxidants in vitro
and in cellular systems, while isomeric MG-H1 and MG-H2 conjugates are completely
inactive under identical conditions. Based on kinetic isotope effect data and computational
results, we believe that MG-H3 conjugates participate in redox reactions through two
distinct mechanisms. In DPPH assays, we postulate this mechanism to involve rate-limiting
H-atom transfer,65 while we speculate the MTT reduction to proceed by way of rate-limiting
single-electron transfer, as previously described.53 Furthermore, results from both
experimental and computational studies support that protonation of MG-H3’s core
heterocycle takes place within the physiological range and diminishes its reactivity,
suggesting a possible role for local pH contexts in regulating MG-H oxidation in vivo.
Finally, we have observed that MG-H3 oxidation leads to spontaneous decomposition to
pyruvate and fully unmodified arginine in aqueous solution. This result provides strong
support for a novel “deglycation” mechanism for MG-H-modified arginine residues, which
may also be relevant in vivo.
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In light of our observations, as well as previous reports, we hypothesize that non-enzymatic
post-translational modification of protein arginine residues may occur in vivo through the
pathway shown in Figure 4. First, unmodified arginine residues react to form MG-H isomers
at a rate related to MGO concentration, pH, and other protein- and context-specific variables
(e.g., subcellular localization, sequence-dependent rate accelerations, etc.), based on
previous studies. Our data suggests that, once formed, MG-H3 adducts are greatly
influenced by their local environment. At physiological pH, MG-H3 adducts are expected to
exist as a nearly equimolar mixture of unprotonated and protonated (MG-H3-H+) forms on
the basis of pKa determinations (Table 2). Thus, upon encountering appropriate oxidizing
agents (e.g., reactive oxygen species or free radicals), un-protonated MG-H3 can undergo a
net two-electron oxidation to yield MG-I3 (Figure 4, Path A), which spontaneously
hydrolyzes to afford arginine and pyruvate. Because oxidation is most likely a faster process
than hydrolysis at neutral pH – for example, DPPH scavenging by peptide 29 has an
observed half-life of approximately 6 minutes (Figure S11), while hydrolysis has a half-life
of 10.5 h (Figures S5–S7) – the possibility exists that significant concentrations of MG-I3
can accumulate physiologically, perhaps leading to protein-protein crosslinking or increased
oxidative stress.67
In situations where protonation is favored (Figure 4, Path B), MG-H3 adducts are protected
from oxidation (Figure 2C, Table 2) and ring-opening.31 They are therefore believed to be
quite stable – the t1/2 of 22free at pH 5.4 and 37 °C is approximately 14.8 days.31 One might
also speculate that the presence of a positive charge in MG-H3-H+ serves to mitigate
destabilizing effects of side-chain modification on protein structure,68 as opposed to other
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MG-H modifications, which would be uncharged at neutral pH. Further studies will be
necessary to investigate these possibilities in detail. Finally, in more basic environments
(Figure 4, Path C), we anticipate that MG-H3 will rapidly convert to carboxyethyl arginine
(CEA) and MG-H1; previous studies have shown these two species to be the predominant
products of MG-H3 hydrolytic cleavage,42 and at pH 9.4, MG-H3 decomposes with a halflife of approximately 20 minutes.31 MG-H1 is also expected to be the most
thermodynamically stable MG-H isomer; our calculations suggest it to be approximately
2.39 kcal/mol lower in energy than MG-H3 (Supporting Information, Table S5), a trend
which is supported by previous experimental studies.42 MG-H1 is therefore expected to
represent a “long-lived” modification of the arginine side-chain that is susceptible neither to
hydrolytic nor oxidative removal. Indeed, MG-H1 is often identified as the major MG-H
formed in vivo,32 perhaps because of its stability relative to MG-H3, and the scarcity of
MG-H2.
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Also worth noting are the apparent functional similarities between MG-H3 and ascorbic acid
in redox assays (Figure 2). Intriguingly, like MG-H3, ascorbic acid has been documented to
serve as a reducing agent through both single-electron-and H-atom-transfer mechanisms,
leaving open the possibility that these species perform similar functions in vivo.69 Similarly,
ascorbate’s paradoxical oxidative activity, observed in vitro in the presence of transition
metals,70 may be mechanistically linked to pro-oxidant effects reported for MGO-modified
proteins.71 Based on reported literature values,17,72 we estimate that concentrations of MGH–arginine adducts can range from 100 nM to 3 μM in plasma or cytosol (higher levels are
observed among diabetic patients), while ascorbate is found in the plasma at approximately
6–60 μM and in cytosol at approximately 35–500 μM.70,73 These rough estimates suggest
that MG-H3 may function as a bulk antioxidant physiologically. Also, the high cellular
permeability of MGO suggests the existence of MG-H–protein adducts both inside and
outside of cells, although these modified proteins themselves may be impermeable.
Taken together, we hypothesize that both formation and removal of MG-H adducts can
occur in a pH- and/or redox-regulated manner, and that these processes could be involved in
normal physiology and perturbed in various disease processes. Validation of this theory will
require follow-up studies of significant scope, which will be enabled by chemically
homogeneous AGE derivatives, and have the potential to implicate MG-Hs and other AGE
family members in a much broader range of life processes than previously suspected.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Stuctures and retrosynthesis of the methylglyoxal-derived hydorimidazolone (MG-H) class
of AGEs. (A) The MG-Hs consist of three isomeric structures as shown, each formed
through condensation of methylglyoxal with arginine. (B) Proposed “divergent”
retrosynthesis of all three isomers derived from a single, readily-available starting material.
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Figure 2.
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MG-H3-containing peptides possess antioxidant activity comparable with ascorbic acid. (A)
Peptides 26–29, 30–33, and ascorbic acid (abbreviated “AA”) were evaluated for their
ability to reduce yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) to purple formazan at room temperature. Data represents the mean of triplicate
experiments ± standard deviation. Data in the indicated columns (***, P < 0.0001) were
found to differ from all other data sets in the Figure using a one-way analysis of variance
(ANOVA) with Tukey’s multiple comparison posthoc test. (B) Radical quenching activity
of peptides 26–29 was determined by treatment with the stable radical 1,1-diphenyl-2picryl-hydrazyl (DPPH). Values represent the mean of triplicate experiments ± standard
deviation. (C) Effect of pH on the observed rate of DPPH quenching by both MG-H3–
peptide and MG-H3-amino acid conjugates. Note that determination of DPPH quenching
rate of free MG-Hs at pH 7 was impeded by high assay background. Values represent the
mean of triplicate experiments ± standard deviation. (D) Antioxidant activity of MG-H–
peptide conjugates in cellular assays. RAW 264.7 macrophages were pre-incubated with
dihydrorhodamine 123, a cell-permeable fluorogenic probe converted to a highly fluorescent
product on exposure to various cellular oxidants, then treated with oxidant (H2O2) and
additive (peptide conjugates or AA). Two treatment regimes were explored; in the first,
oxidant concentration was varied at a fixed level of additive (left-hand panel), while in the
second, additive was varied at a fixed amount of oxidant (right-hand panel). Reported
“Antioxidant Activity” values reflect the extent to which each additive is capable of
suppressing H2O2-induced fluorescence. These values (± standard error) were calculated
from linear least-squares fits of fluorescence intensity data plotted versus additive
concentration as detailed in the supporting information. P-values (two-tail) represent the
probabilities that pair-wise differences in slope (plus versus minus additive) could have
arisen from randomly chosen data points, and are reported as follows: ***, P < 0.0001; *, P
< 0.05. All reported trends were observed on at least two separate occasions.
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Figure 3.

LC/MS and LC/MS-MS analyses of hydroimidazolone-peptide conjugates in MTT
antioxidant assays. (A) LC traces of MTT assay reaction mixtures. Two new peaks are
observed in assays involving peptide 29, while experiments employing peptides 26, 27, and
28, indicate only starting materials. (B) Mass spectra corresponding to material contained in
the LC peaks labeled 1 and 2 in panel A. These experiments indicate a loss of two mass
units in newly formed material versus the parent peptide 29. (C) LC/MS-MS fragmentation
analysis of material in peak 2. This data suggests that the decrease in reaction product mass
originates at the MG-H3-modified residue. (D) Schematic reaction mechanism illustrating
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the overall transformation from MG-H3-modified peptide 29 to the corresponding Argmodified sequence (26) and pyruvate (35) by way of imidazolone 34. For simplicity, one
representitve MG-H3 tautomer is shown; the rest are provided in Scheme S4.
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Figure 4.
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Proposed model for the regulation of arginine glycation. Accessible Arg sidechains react
with MGO to form a mixture of isomeric MG-H adducts, of which MG-H3 is believed to be
the kinetic product. MG-H3 is sensitive toward local perturbations in pH or redox balance.
Path A. At neutral pH, MG-H3 undergoes rapid oxidative conversion to MG-I3, which then
spontaneously hydrolyzes to regenerate Arg plus one equivalent of pyruvate. Path B. In the
presence of low local pH or nearby protic residues, MG-H3-H+ is formed, and this species is
likely stable and relatively insensitive to changes in redox balance. Path C. At higher local
pH or in the presence of basic residues, however, ring-opening of MG-H3 affords
carboxyethylarginine (CEA) and MG-H1, which both appear to be relatively
environmentally insensitive. *For simplicity, only one of two likely MG-H3 tautomers is
shown. Please see Supporting Information (Scheme S4) for more detail.
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Scheme 1.
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Scheme 2.
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Scheme 3.
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Table 1

Synthesis of Hydroimidazolone-containing peptides
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Entry

compound

HSA fragments

Peptide Sequences

Isolated Yielda

1

23

n/a

LG-(MG-H1)-AG

32%

2

24

n/a

LG-(MG-H2)-AG

33%

3

25

n/a

LG-(MG-H3)-AG

47%

4

26

407 – 415

LLV-R-YTKKV

46%

5

27

407 – 415

LLV-(MG-H1)-YTKKV

59%

6

28

407 – 415

LLV-(MG-H2)-YTKKV

37%

7

29

407 – 415

LLV-(MG-H3)-YTKKV

55%

8

30

111 – 120

NLP-R-LV-R-PEV

33%

9

31

111 – 120

NLP-(MG-H1)-LV-(MG-H1)-PEV

39%

10

32

111 – 120

NLP-(MG-H2)-LV-(MG-H2)-PEV

36%

11

33

111 – 120

NLP-(MG-H3)-LV-(MG-H3)-PEV

49%

a

Peptides were isolated in >95% purity
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3.58
3.81
7.44
N/R

4.58

4.68

7.70

N/R

36

37

38

39

76.4

68.3

76.5

76.2

BDE (kcal/mol)f

186.9

141.0

150.6

153.2

IE (kcal/mol)g

N/R

23.8

22.3

26.0

ΔGox(kcal/mol)h
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Calculated pKa, determined as detailed in the supporting information.

Data corresponds to the free energy difference between the indicated MG-H and the corresponding imidazolone oxidation product, as described in the supporting information.

h

IE = ionization energy.

g

BDE = bond dissociation energy.

f

e

pKa values were obtained experimentally via NMR titration.

Calculations pretaining to the other MG-H3 tautomer can be found in the supporting information.

d

c

supporting information.

All calculations were performed utilizing the Gaussian 09 program suite. Geometry optimizations were performed using the 6–31+G(d) basis set, and single-point energies determined at the 6–311+
+G(2df,2p) level. All calculations implemented a continuum model to account for the effects of water solvent, l.p. = lone pair. Additional details regarding pKa titrations and calculations can be found in the

b

R = Orn for compounds employed in pKa measurements, and R = Me for structures used in calculations. Calculations involving the energies of relevant tautomeric and protonated forms can be found in
the online supporting information.

a

calc’d pKae

pKad

Cmpd

pKa Values and Calculated Energies for MG-H Deriva-tives. a,b
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